Lyell Immunopharma, Inc.
LYEL
$10.64
-$0.33-3.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.82% | 13.96% | -262.62% | 12.33% | 28.30% |
| Total Depreciation and Amortization | -36.03% | -31.51% | -0.61% | -8.31% | -3.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.36% | -78.83% | 2,431.42% | -32.16% | -76.57% |
| Change in Net Operating Assets | 8.18% | -195.15% | -98.03% | -57.25% | -126.62% |
| Cash from Operations | 9.54% | -30.28% | -16.26% | 7.02% | 2.72% |
| Capital Expenditure | 49.24% | -720.00% | -76.00% | 69.74% | 64.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.73% | 216.53% | 184.33% | -98.02% | -70.53% |
| Cash from Investing | -71.90% | 215.84% | 153.14% | -98.08% | -70.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.65% | -- | -50.45% | -100.00% | -30.82% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -78.77% | -96.30% | -42.42% | 100.00% | -27.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -378.17% | 173.66% | 104.77% | -153.56% | -93.24% |